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Treatment on the Basis of Perceived Risk*Andrew E. Epstein, MDSEE PAGE 2607T he Device-Based Therapy Guidelines from theAmerican College of Cardiology, AmericanHeart Association, and Heart Rhythm Society
detail indications for implantable cardioverter-
deﬁbrillator (ICD) implantation in patients with
ischemic cardiomyopathy (ICM) and nonischemic
cardiomyopathy (NICM) (1). Primary prevention ICD
implantation is indicated for patients with ICM and a
left ventricular ejection fraction (LVEF) #35%, at least
40 days post-myocardial infarction (MI), and New
York Heart Association (NYHA) functional class II or
III. For those with NYHA functional class I, the LVEF
requirement is #30%. For patients with NICM, the
indication is for patients with a LVEF #35% and
NYHA functional class II or III. Although the recom-
mendations do not specify waiting periods of 90
days for patients with ICMwho undergo revasculariza-
tion and for patients with NICM whose medical ther-
apy is being optimized, they are assumed because
the guidelines reference the trials, speciﬁcally,
the MADIT-II (Multicenter Automatic Deﬁbrillator Im-
plantation Trial II) (2) and the SCD-HeFT (Sudden Car-
diac Death-Heart Failure Trial) (3), that provide the
basis for the recommendations, respectively.
Given these waiting periods, how do I manage pa-
tients with newly diagnosed cardiomyopathy referred
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St. Jude Medical.being optimized? If I recommend and implant
ICDs during these waiting periods, what are my
liabilities? In addition to not practicing evidence-
based medicine, there are other elephants in the
room: the National Coverage Determination (4) and
the Department of Justice investigation of inappro-
priate ICD implantation (5). The National Coverage
Determination is the legal basis of reimbursement
eligibility by Medicare (Centers for Medicare &
Medicaid Services), and billing for noncovered im-
plantation may be represented as fraud. Should I
worry about not implanting an ICD and recommend-
ing optimization of medical therapy while waiting to
see if the LVEF justiﬁes an ICD after 3 months of good
therapy? Another option is a wearable cardioverter-
deﬁbrillator (WCD). What are the data that this is
the right thing to do? Is it for everyone, or only for
selected patients?In this issue of the Journal, Singh et al. (6) examine
the utility of using a WCD in patients with newly
diagnosed cardiomyopathy to prevent sudden
arrhythmic death while medical therapy is being
optimized and re-evaluation of left ventricular func-
tion is awaited. While hospitalized between June 2004
and May 2015, 271 patients with newly diagnosed ICM
and 254 patients with newly diagnosed NICM were
prescribed a WCD. The primary study endpoint was
appropriate WCD therapy. The median WCD wear
time was 61 days per patient and 22 h/day. During
46.7 patient-years of follow-up, 6 patients with
ICM (2.2%) received an appropriate shock; 5 survived
the episode, and 4 survived to hospital discharge,
thus reducing the effectiveness rate to 1.5%. All
6 patients with an appropriate shock were male
with a QRS duration >120 ms. Two patients with
ICM (0.7%) received inappropriate shocks. During
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appropriate WCD shock, whereas 3 (1.2%) received an
inappropriate shock. The investigators concluded
that there was minimal risk of appropriate WCD
therapy in patients with newly diagnosed NICM, that
routine WCD use in this population should be pro-
spectively evaluated, and that the risk of appropriate
therapies in patients with newly diagnosed ICM was
comparable to that in prior observational studies. The
implication is that prescribing a WCD for patients
with newly diagnosed ICM was reasonable. These
data must be interpreted with the understanding that
the number of patients with similar characteristics
who were excluded from the analysis because they
did not receive a WCD or because follow-up data
were incomplete or not retrievable is unknown.
Furthermore, the zero event rate for the patients with
NICM is problematic because the play of chance may
lead to this result when the sample size is small, as in
this study.
Are there data that ICDs improve survival early
post-MI or the diagnosis of newly diagnosed cardio-
myopathy? If not, why would one expect beneﬁt from
a WCD? In MADIT II, patients with prior MI and an
LVEF #30% were randomized to receive either opti-
mized medical therapy (OMT) or OMT with an ICD (2).
The study showed clear beneﬁt from ICD implanta-
tion. Exclusions to enrollment included MI within
1 month or revascularization within 3 months of the
index infarction. Even with these waiting periods, the
survival curves did not separate until months after
randomization. Furthermore, during the waiting
period after MI, neither the DINAMIT (Deﬁbrillator in
Acute Myocardial Infarction Trial) (7) nor the IRIS
(Immediate Risk Stratiﬁcation Improves Survival)
study (8) showed survival beneﬁt with early ICD im-
plantation. Notably, in both studies, arrhythmic
death was less in the ICD groups compared to con-
trols, but exactly counterbalanced by nonarrhythmic
death in the ICD groups.
The reason for this apparent paradox might be that
the “phenotype” of sudden arrhythmic death does
not imply mechanism. In VALIANT (Valsartan in
Acute Myocardial Infarction Trial), 19% of all sudden
deaths or cardiac arrests occurred in the ﬁrst month,
at a rate of 1.4% per month, and 83% of sudden deaths
in the ﬁrst month occurred after hospital discharge,
suggesting that resuscitation could save some of
these lives (9). However, in a subanalysis of 105 pa-
tients who had died suddenly and had autopsies, only
54 deaths could be attributed to an arrhythmic origin
(10). Overall, autopsy led to reassignment of cause of
the death in 17%, with MI and rupture being most
common. Thus, the actual rate of early suddenarrhythmic death was overestimated in VALIANT.
Importantly, arrhythmic death increased from 20% in
the ﬁrst month to 75% later in the study, in keeping
with the known long-term beneﬁts of ICD therapy.
Thus, implantation of an ICD within 40 days of an MI
is not appropriate.
There is also ample information regarding the
timing of ICD implantation in patients with NICM.
CAT (Cardiomyopathy Amiodarone Trial) (11) enrolled
patients with NICM, an LVEF #30%, and duration of
heart failure #9 months. Randomization was to OMT
alone or OMT with an ICD; the study was stopped
early for futility. In the DEFINITE (Deﬁbrillators in
Non-Ischemic Cardiomyopathy Treatment Evalua-
tion) trial, patients with NICM, NYHA functional class
I to III, LVEF <36%, and ventricular ectopy were
randomized to OMT alone or OMT with an ICD, with
no restriction on cardiomyopathy duration for entry
(12). The primary endpoint was death from any cause,
and statistical difference was not achieved. Finally,
SCD-HeFT included patients with ICM and NICM,
NYHA functional class II to III heart failure, and
LVEF #35%; patients were randomized to OMT, OMT
with amiodarone, or OMT with an ICD (3). All patients
were treated for 3 months before enrollment. The
primary endpoint was death from any cause.
Although ICDs decreased the risk of death compared
with control (27% for NICM), beneﬁt did not become
apparent for more than a year. Thus, as with ICM,
there is no evidence that early ICD implantation
beneﬁts patients with newly diagnosed NICM.
Several studies related to the WCD are also
available. All were observational and none was ran-
domized, as is the present study. Zishiri et al. (13)
compared survival post-revascularization in patients
with a LVEF #35%, discharged either with or without
a WCD. Early mortality was lower among 809 patients
discharged with a WCD compared to 4,149 patients
discharged without a WCD (90-day mortality post
coronary artery bypass graft surgery 3% vs. 7%,
p ¼ 0.03; postpercutaneous coronary intervention
2% vs. 10%, p < 0.0001). WCD use was associated with
statistically signiﬁcant adjusted lower risks of long-
term mortality in both the postcoronary artery
bypass graft (38%) and postpercutaneous coronary
intervention (57%) cohorts (mean follow-up,
3.2 years). Notably, mortality differences were not
attributable solely to therapies for ventricular
arrhythmias, as only 1.3% of the WCD group had a
documented appropriate therapy. Epstein et al. (14)
described the outcomes of patients prescribed a
WCD in the ﬁrst 3 months post-MI. Of 8,453 patients,
133 (1.6%) received appropriate shocks, and 91% were
resuscitated. The median time from the index MI to
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75% received treatment in the ﬁrst month, and
96% within the ﬁrst 3 months of use. The in-
vestigators concluded that during the 40-day and
3-month waiting periods post-MI, the WCD success-
fully treated sudden cardiac arrest in 1.4%.
Finally, the WEAR-IT (Prospective Registry of Pa-
tients Using the Wearable Deﬁbrillator trial) (15)
reported outcomes of 2,000 patients with ICM
(n ¼ 805, 40%), NICM (n ¼ 927, 46%), or congenital/
inherited heart disease (n ¼ 268) treated with a WCD.
The median age was 62 years, LVEF 25%, WCD
wear-time 90 days, and daily use 22.5 h. There
were 120 sustained ventricular tachyarrhythmias
(ventricular tachycardia/ﬁbrillation) in 41 patients,
of whom 54% received an appropriate shock. The
rate of sustained ventricular tachycardia/ﬁbrillation
by 3 months was 3% among patients with ICM
and congenital/inherited heart disease, and 1%
among those with NICM (p ¼ 0.02). The investigators
concluded that the WCD can protect patients while
optimizing medical therapy and further assessing risk.
It is remarkable that the present study and those
just reviewed showed similarly low frequencies of
WCD therapy in the ﬁrst months of use. A recent cost
analysis found that WCD cost was <$100,000 per
quality-adjusted life year gained, as long as the rate of
cardiac arrest in the ﬁrst month post-MI was $1.163%.
(16) This threshold was achieved in each of these
studies! However, there were no “entry criteria” for
who should be prescribed a WCD. Rather, the decision
was made on the basis of clinical judgment and “gutfeeling” of perceived risk. Although one viewpoint is
that physicians responsible for the WCD literature
should be commended for having done a pretty good
job of using their bedside instincts, more rigorous
evidence is needed. Only hospitalized patients were
represented in the present study, and the risk for
patients identiﬁed as outpatients may be lower (17).
This would decrease cost-effectiveness and increase
the number needed to treat. Furthermore, in the
present study, the patients receiving an appropriate
WCD shock were male with prior revascularization
and a wide QRS. Could risk be further reﬁned to focus
on such patients? For patients who are post-MI, the
answer may come from the VEST (Vest Prevention of
Early Sudden Death Trial) and Registry, hopefully
available later this year (18). However, for newly
diagnosed NICM, there are no randomized trial data
and, because the event rate is apparently so low, a
study large enough to evaluate the use of the WCD
while optimizing therapy will likely not be done.
Even if positive, the number needed to treat and cost
to save one life would be so large that it might be
unacceptable. Thus, we must rely on data such as that
presented by Singh et al. (6) and make our decisions
at the bedside.
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